Measurement of anti-SARS-CoV-2 antibodies nucleocapsid versus spike, ECLIA versus ELISA

Czech version

Authors: K. Bořecká ¹; V. Jamriková ¹; P. Sojka ²; Z. Khaznadar ²; M. Ibrahimová ²
Authors‘ workplace: Oddělení klinické biochemie, Fakultní Thomayerova nemocnice, Praha ¹; Imunologická laboratoř, Fakultní Thomayerova nemocnice, Praha ²
Published in: Klin. Biochem. Metab., 29, 2021, No. 1, p. 19-24

Overview

Objective: The aim of this study is to provide information on the comparison of the determination anti-SARS-CoV-2 antibodies by two differently designed assays, ECLIA (Roche Diagnostics) and ELISA (Euroimmun).

Settings: Department of Clinical Biochemistry and Immunology Laboratory, Thomayer University Hospital

Materials and Methods: We selected 134 serum samples from 90 patients, Thomayer Hospital staff, and convalescent plasma donors (33 PCR-negative and 57 PCR-positive) at various intervals from the onset of clinical symptoms (1-136 days). We examined anti-SARS-CoV-2 antibodies simultaneously by ELISA in the IgG and IgA classes (DSX) and ECLIA (Cobas e602) and statistically processed the results. By measuring control materials, positive and negative pools we evaluated selected analytical characteristics.

Results: We found a high degree of agreement between ELISA and ECLIA. Specificity and sensitivity were very high in both tests, the sensitivity increasing with the distance from the beginning of the symptoms with a maximum of more than 20 days. For ECLIA, the sensitivity may be further increased by application an optimized cut-off. Antibodies persisted to a high degree after 60 days from the onset of symptoms, especially in the IgG class. Intermediate precision and repeatability suited clinical purposes.

Conclusion: Both methods are very useful serological monitoring of the antibody response status to SARS-CoV-2 infection. ECLIA method using a highly immunogenic nucleocapsid antigen that captures high affinity antibodies of all classes is preferable for daily routine and the rapid screening. ELISA tests with a conservative spike protein can then be used to confirm and distinguish individual immunoglobulin classes.

Keywords:

antibodies anti-SARS-CoV-2 – COVID-19 – sensitivity – specificity

Sources

SARS-CoV-2. Diagnostic pipeline. [online] [cit. 2020-12-08]. Dostupný na www: www.finddx.org.
Friedecký, B., Kratochvíla, J. Laboratorní aspekty COVID-19. Diagnostika, epidemiologie, prognóza pacientů. Klin. Biochem. Metab., 2020, 28(49), č. 3, s. 97–105.
Okba, N. M. A., Mueller, M., A., Li, W., Wang, Ch., Geurtsvan Kessel, Ch. et al. Severe Acute Respiratory Syndrome Coronavirus 2-Speci-fic Antibody Responses in Coronavirus Disease 2019 Patients. Emerg. Infect. Dis., 2020, 26(7), s. 1478–1488.
Sethuraman, N., Jeremiah, S. S., Ryo, A. Interpreting diagnostic test for SARS-CoV-2. JAMA, 2020, 323(22), s. 2249–2251.
Padoan, A., Sciacovelli, L., Basso, D. et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study, Clin. Chim. Acta, 2020, 507, s. 164–166.
Long, Q. X., Liu, B. Z., Deng, h. J. et al. Antibody responses to SARS-CoV-2 in patient with COVID-19. Nat Med, 2020, 26(6), s. 845–848.
Krejsek J., Andrýs C., Krčmová I. Imunologie člověka, 1. vydání. Hradec Králové: Garamon s.r.o., 2016, 496 s. ISBN-13: 978-80-86472-74-4.
Lochman, I., Kratochvíla, J., Friedecký, B. Laboratorní diagnostika COVID-19. Klin. Biochem. Metab., 2020, 28(49), č. 3, s. 93–96.
Elecsys Anti-SARS-CoV-2. Příbalová informace, 2020-11, V3.0; Material Numbers 09203095190.
EUROIMMUN. Anti-SARS-CoV-2 ELISA IgG, Příbalová informace. EI_2606G_A_CZ_C04.docx Version: 2020-05-07.
EUROIMMUN. Anti-SARS-CoV-2 ELISA IgA, Příbalová informace. EI_2606A_A_CZ_C04.docx Version: 2020-05-07.
Egger, M., Bundschuh, Ch., Wiesinger, K. et al. Comparison of the Elecsys Anti-SARS-CoV-2 immunoassay with the EDI enzyme linked immunosorbent assays for detection of SARS-CoV-2 antibodies in human plasma. Clin. Chim. Acta, 2020, 510, s. 73–78.
Favresse, J., Eucher C., Elsen, M., Marie, T. H., Dogne, J. M., Douxfils, J. Clinical performance of the elecsys electrochemiluminiscent immunoassay for the detection of SARS-CoV-2 total antibodies. Clin. Chem, 2020, 66(8), s. 1104–1106.
Chan, C. W., Parker, K., Tesic, V. et al. Analytical and Clinical Evaluation of the Automated Elecsys Anti–SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer. Am. J Clin. Pathol., 2020, aqaa155, doi: 10.1093/ajcp/aqaa155.
Hörber, S., Soldo, J., Relker, L. et al. Evaluation of three fully automated SARS-CoV-2 antibody assays. Clin. Chem. Lab. Med., 2020, 58(12), s. 2113–2120.
Surkova, E., Nikolayevskyy, V., Drobniewski, F. False-positive COVID-19 results: hidden problems and costs. Lancet Respir. Med., 2020, 8(12), s. 1167–1168.
Watson, J., Whiting, P. F., Brush, J. E. Interpre-ting a covid-19 test result. BMJ, 2020, 369, m1801, doi: 10.1136/bmj.m1808.
Valent, F., Doimo, A., Mazzilis, G., Pipan, C. RT-PCR tests for SARS-CoV-2 processed at a large Italina Hospital and false-negative results among confirmed COVID-19 cases. Infect. Control Hosp. Epidemiol., 2020, 1–2, doi: 10.1017/ice.2020.290.
Kucirka, l. M., Lauer, S. A., Laeyendecker, O., Boon, D., Lessler, J. Variation in false-negative rate of reverse transcriptase polymerase chain reaction-based SARS-CoV-2 tests by time since exposure. Ann. Intern. Med., 2020, M20–1495, doi: 10.7326/M20-1495.
Guo, L., Ren, L., Yang, S. et al. Profiling early humoral response to diagnose Novel corona-virus disease (COVID-19). Clin. Infect. Dis., 2020, 71(15), s. 778–785.
Fierz, W., Walz, B. Antibody dependent enhancement due to original antigenic sin and the development of SARS. Front. Immunol., 2020, 11, 1120, doi: 10.3389/fimmu.2020.01120.

Labels

Clinical biochemistry Nuclear medicine Nutritive therapist

EDITORIAL

Quantitative determination of hemoglobin in stool - preanalytical and analytical aspects

Overview of biomarkers of synovial fluid in joint diseases

Analytes of clinical biochemistry and hematology in COVID-19

Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře: POCT metody v ordinaci praktického lékaře

Doporučení České společnosti klinické biochemie ČLS JEP k využití nádorových markerů v klinické praxi

Article was published in

Clinical Biochemistry and Metabolism

2021 Issue 1